Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.78
+0.03 (0.39%)
Dec 20, 2024, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $702.47M in the quarter ending September 30, 2024, with 13.29% growth. This brings the company's revenue in the last twelve months to $2.68B, up 12.32% year-over-year. In the year 2023, Amneal Pharmaceuticals had annual revenue of $2.39B with 8.20% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+12.32%
P/S Ratio
0.85
Revenue / Employee
$341,455
Employees
7,850
Market Cap
2.41B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Select Medical Holdings | 6.97B |
Privia Health Group | 1.72B |
Addus HomeCare | 1.13B |
Tandem Diabetes Care | 854.35M |
Catalyst Pharmaceuticals | 460.48M |
Beam Therapeutics | 349.64M |
Protagonist Therapeutics | 323.80M |
NewAmsterdam Pharma Company | 33.59M |
AMRX News
- 17 days ago - Amneal to Participate at Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Business Wire
- 6 weeks ago - Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Amneal Reports Third Quarter 2024 Financial Results - Business Wire
- 2 months ago - Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Business Wire
- 2 months ago - Amneal to Report Third Quarter 2024 Results on November 8, 2024 - Business Wire
- 2 months ago - Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases - Business Wire
- 3 months ago - Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease - Business Wire